Data from: Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma

Brian J. Capaldo, Devin Roller, Mark J. Axelrod, Alex F. Koeppel, Emanuel F. Petricoin, Craig L. Slingluff, Michael J. Weber, Aaron J. Mackey, Daniel Gioeli & Stefan Bekiranov
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms of intrinsic and adaptive resistance and develop drug combinations that target these resistance mechanisms. In a combinatorial drug screen on a panel of 12 treatment-naïve BRAFV600E mutant melanoma cell lines of varying levels of resistance to mitogen-activated protein...
1 citation reported since publication in 2016.
484 views reported since publication in 2016.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
149 downloads reported since publication in 2016.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?